Skip to main content

Peer Review reports

From: Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

Original Submission
22 Jan 2018 Submitted Original manuscript
2 May 2018 Reviewed Reviewer Report - Dhaval Patel
19 Jul 2018 Reviewed Reviewer Report - Silvia Martina Ferrari
30 Aug 2018 Author responded Author comments - Janice Mehnert
Resubmission - Version 2
30 Aug 2018 Submitted Manuscript version 2
18 Sep 2018 Reviewed Reviewer Report - Dhaval Patel
4 Feb 2019 Author responded Author comments - Janice Mehnert
Resubmission - Version 3
4 Feb 2019 Submitted Manuscript version 3
13 Feb 2019 Author responded Author comments - Janice Mehnert
Resubmission - Version 4
13 Feb 2019 Submitted Manuscript version 4
Publishing
19 Feb 2019 Editorially accepted
4 Mar 2019 Article published 10.1186/s12885-019-5380-3

You can find further information about peer review here.

Back to article page